Moderna Experiences Significant Share Drop
In recent trading, shares of Moderna (NASDAQ: MRNA) faced a notable decline, slipping over 17% during premarket hours. This downturn comes following the company's revised revenue guidance for 2025, raising questions about its future performance.
Adjusted Revenue Forecast
Moderna's leadership has set the company's annual sales estimate between $1.5 billion and $2.5 billion, a stark reduction from previous projections of $2.5 billion to $3.5 billion. Market analysts had anticipated even higher sales, with consensus estimates reaching up to $2.92 billion.
The bulk of Moderna's revenue is expected in the latter half of 2025, primarily stemming from the sales of its widely known vaccines, Spikevax and mRESVIA.
Performance of Key Vaccines
For context, the Spikevax COVID-19 vaccine generated impressive revenue, achieving $1.8 billion in sales during the third fiscal quarter, bolstered by sustained demand across various markets. However, the sales figures for mRESVIA, which targets respiratory syncytial virus, fell short of expectations, only bringing in $10 million against analytics predictions of approximately $135 million.
Cost Efficiency Initiatives
In light of these changes, Moderna announced that it is intensifying efforts related to cost efficiency and business prioritization. The company projects cash cost reductions totaling $1 billion for 2025, with an additional potential saving of $500 million earmarked for 2026.
2024 Sales Projections
As for the upcoming year, Moderna anticipates product sales to land between $3 billion and $3.1 billion, segregated into approximately $1.7 billion from US markets and around $1.3 billion to $1.4 billion globally. The 2024 forecast includes an expected $3 billion in Spikevax sales along with minimal revenues from mRESVIA.
Operational Cost Reduction
In an encouraging note, the company announced a significant reduction in full-year cash operating expenses by 25% compared to 2023 figures, which may help bolster their financial standing amid these challenges.
Strategic Focus Areas
CEO Stephane Bancel emphasized the organization's commitment to three main strategic priorities: driving sales growth, aiming for up to 10 new product approvals over the next three years, and implementing cost-reduction strategies throughout the business.
Looking Ahead
Earlier this year, Moderna had foreseen 2024 sales ranging between $3 billion and $3.5 billion, even as the company braces for a decline in revenue from its COVID-19 vaccine compared to the previous fiscal year. Projected fourth-quarter sales are expected to be between $200 million and $500 million, conditioned on stable or declining COVID vaccination rates through the year.
Frequently Asked Questions
What caused the drop in Moderna's share price?
The decline is primarily attributed to a significant reduction in revenue guidance for 2025 announced by Moderna.
What are Moderna's new revenue projections for 2025?
Moderna's revised revenue forecast for 2025 ranges between $1.5 billion and $2.5 billion.
Which vaccines contribute to Moderna's revenue?
The two main vaccines are Spikevax for COVID-19 and mRESVIA for respiratory syncytial virus.
What cost-saving measures is Moderna implementing?
Moderna is aiming for cash cost reductions of $1 billion in 2025 and an additional $500 million in 2026, focusing on efficiency improvements.
How does Moderna plan to grow its revenue in the coming years?
Moderna plans to focus on increasing sales, obtaining new product approvals, and reducing operational costs to foster growth.
